A review study on Guillain barre syndrome
1 Department of Pharmacy Practice, Vignan Pharmacy College (Autonomous), Vadlamudi, Guntur, Andhra Pradesh, India.
2 Department of Pharmaceutics, Vignan Pharmacy College (Autonomous), Vadlamudi, Guntur, Andhra Pradesh, India.
Review
World Journal of Biology Pharmacy and Health Sciences, 2024, 20(03), 085–093.
Article DOI: 10.30574/wjbphs.2024.20.3.0947
Publication history:
Received on 18 October 2024; revised on 02 December 2024; accepted on 05 December 2024
Abstract:
Acute immune-mediated peripheral nerve system dysfunction known as Guillain-Barre Syndrome (GBS) is typified by rapidly worsening muscle weakness, which frequently begins in the lower limbs and can eventually result in paralysis. It is typically brought on by an infectious event, most often a bacterial or viral infection, with Campylobacter jejuni being the most often linked harmful organism. According to epidemiology, there are 1-2 instances of GBS for every 100,000 people each year, with a small male predominance and greater frequency in adults over 50. Nerve conduction investigations and cerebrospinal fluid analysis demonstrating albumin cytological separation complement the largely clinical diagnosis.
Keywords:
Autoimmune Neurological Disorder; Peripheral Nerve Damage; Demyelination; Immune-mediated Nerve Injury; Plasma Exchange (PE); Intravenous Immunoglobulin (IVIg).
Full text article in PDF:
Copyright information:
Copyright © 2024 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0